Lobaplatin versus cisplatin in concurrent chemoradiotherapy for elderly cervical cancer: randomized controlled phase II study
Lobaplatin-based CCRT demonstrates comparable efficacy to cisplatin in elderly cervical cancer patients, with superior renal safety and improved gastrointestinal tolerability, establishing it as a viable alternative for cisplatin-intolerant populations.
Authors
- Fan Mei (ORCID: https://orcid.org/0000-0002-3707-8800)
- Fenghu Li (ORCID: https://orcid.org/0000-0002-6522-8394)
- Lili Hu (ORCID: https://orcid.org/0000-0002-3683-9954)
- Y Q DU (ORCID: https://orcid.org/0000-0002-8826-7871)
- Jie-Hui Li (ORCID: https://orcid.org/0000-0002-5204-0149)
Institutions
- Guiyang Medical University (CN)
- Guizhou Cancer Hospital (CN)
- Affiliated Hospital of Guizhou Medical University (CN)
Publication Details
- Journal
- Journal of Gynecologic Oncology
- Published
- 2025-12-08
- DOI
- https://doi.org/10.3802/jgo.2026.37.e33
- Primary Topic
- Chemotherapy-induced organ toxicity mitigation
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Health Commission of Guizhou Province